Alembic and Biocon kick off the Q1 earnings season in India with significant growth in the active pharmaceutical ingredients business and expect to see continued momentum in the area. More Indian firms could gain as customers realign strategies and move away from single sources to de-risk their supply chain, learning from pandemic-related disruptions.
The first-quarter fiscal 2021 earnings of India's Alembic Pharmaceuticals Limited and Biocon, Ltd. have reflected strong traction in the active pharmaceutical ingredients (APIs) business against the backdrop of coronavirus pandemic-related disruptions as customers stocked up to ensure business continuity.
While APIs are not the biggest contributor to the revenues of both the front-line companies, which have distinct profiles and...
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers
Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.
With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.
